COVID-19 in vaccinated versus unvaccinated hematologic malignancy patients.

Catherine DeVoeShraddha PandeyDayana ShariffShagun AroraTimothy J HenrichDeborah S YokoeCharles R LangelierVenice ServellitaCharles ChiuSteve MillerJennifer M BabikPeter Chin-HongMonica Fung

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2022)

The effect of vaccination on severity of subsequent COVID-19 in patients with hematologic malignancies (HMs) is unknown. In this single-center retrospective cohort study, we found no difference in severity of COVID-19 disease in vaccinated (n = 16) versus unvaccinated (n = 54) HM patients using an adjusted multiple logistic regression model. Recent anti-B-cell therapy was associated with more severe illness.

Keyphrases

coronavirus disease
end stage renal disease
sars cov
cell therapy
newly diagnosed
chronic kidney disease
ejection fraction
prognostic factors
peritoneal dialysis
mesenchymal stem cells
bone marrow
patient reported outcomes
early onset